膀胱癌患者の細胞性免疫能に関する研究 第5報: LAI testにおける患者血清のblocking,unblocking効果について

Abstract

The specific immune reactivities of leukocytes to tumor associated antigens and specific serum immune reactivities of leukocytes to tumor associated antigens and specific serum factors in cancer patients were studied on 10 urinary bladder carcinoma, 4 prostatic carcinoma, 3 renal carcinoma and 10 control subjects. The specific reactivities were measured by means of leukocyte adherence inhibition test(LAI) following Halliday et al. and LAI index was calculated. Autologous and allogeneic crude extracts were prepared from resected bladder carcinoma and prostatic sarcoma tissues for antigens. Tumor and normal tissues were homogenized and centrifuged at 20, 000 g, 4°C for 60 minutes. Supernate filtered by millipore filter (0.45 fl) was used as antigen. Final concentration of tissue extracts was adjusted to 100 µg/ml of protein that was optimal dose as antigen. Sera used in this experiment were taken from patients with urinary bladder carcinoma before and after operation, renal carcinoma, prostatic carcinoma and normal subjects. When leukocytes from patients with bladder carcinoma were challenged against transitional cell carcinoma extract(TCC-extract), LAI index was about 0.58. But leukocytes from normal subjects or other patients with urological malignant diseases showed no reaction against TCC-extracts. The reaction of leukocytes from preoperative bladder carcinoma patients to TCC-extracts could be blocked by sera from bladder carcinoma patients before operation. Otherwise the leukocytes from the same patient did not show LAI reaction against prostatic sarcoma extract and there was no blocking effect of sera. The present study also demonstrated that sera from bladder carcinoma patients after operation, who were clinically tumor-free, could unblock the blocking effect of sera from bladder carcinoma patients before operation. And it was shown that the blocking and unblocking effects of sera from bladder carcinoma patients might be exchanged each other on 3 to 6 months after operation. Immunological parameters and immunotherapy were discussed about urinary bladder carcinoma patients.